In a phase 1/2 trial of 89 adults with dry eye disease, eye drop SJP-0132 versus placebo was well tolerated with mild adverse events only; eye dryness scores fell but not significantly versus placebo, and corneal staining fell with a similar dose dependence.
RCTn = 89
Wada et al. Results of a Randomized, Double-Masked, Placebo-Controlled Phase 1/2 Study of a TRPV1 Antagonist SJP-0132 in Participants With Dry Eye Disease